Valneva SE (VALN) Shares Outstanding (Weighted Average) (2020 - 2026)
Valneva SE's (VALN) quarterly Shares Outstanding (Weighted Average) came in at $30.5 million in Q1 2026, up 19.08% year-on-year from $25.6 million in Q1 2025, and up 0.77% quarter-over-quarter from $30.3 million in Q4 2025.
Valneva SE (VALN) Shares Outstanding (Weighted Average) (2020 - 2026) Analysis & Trends
Valneva SE has disclosed Shares Outstanding (Weighted Average) across 7 years of filings, most recently posting $30.5 million for Q1 2026.
- Shares Outstanding (Weighted Average) for Q1 2026 came in at $30.5 million, up 19.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.5 million (up 19.08% YoY), and the FY2025 annual result was $30.3 million, down 82.54% from the prior year.
- Shares Outstanding (Weighted Average) came in at $30.5 million for Q1 2026 at Valneva SE, up from $30.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $173.5 million in Q4 2024 to a low of $269.36 in Q1 2022.
- The 5-year median for Shares Outstanding (Weighted Average) is $25.6 million (2025), against an average of $45.2 million.
- Across the five-year window, Shares Outstanding (Weighted Average) surged 8269094.54% in 2023 and slumped 82.54% in 2025, its largest moves.
- Valneva SE's Shares Outstanding (Weighted Average) stood at $141.0 million in 2022, then increased by 5.87% to $149.3 million in 2023, then rose by 16.21% to $173.5 million in 2024, then plunged by 82.54% to $30.3 million in 2025, then advanced by 0.77% to $30.5 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $30.5 million (Q1 2026), $30.3 million (Q4 2025), and $30.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 417.01 Bn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 928.40 Mn |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 30.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.54 Mn |
| Dec 31, 2025 | 30.30 Mn |
| Sep 30, 2025 | 30.14 Mn |
| Jun 30, 2025 | 28.90 Mn |
| Mar 31, 2025 | 25.64 Mn |
| Dec 31, 2024 | 173.54 Mn |
| Sep 30, 2024 | 26.73 Mn |
| Jun 30, 2024 | 22.50 Mn |
| Mar 31, 2024 | 22.70 Mn |
| Dec 31, 2023 | 149.33 Mn |
| Sep 30, 2023 | 22.68 Mn |
| Jun 30, 2023 | 22.69 Mn |
| Mar 31, 2023 | 22.27 Mn |
| Dec 31, 2022 | 141.04 Mn |
| Sep 30, 2022 | 927.61 |
| Jun 30, 2022 | 18.78 Mn |
| Mar 31, 2022 | 269.36 |
| Dec 31, 2021 | 120.25 Mn |
| Sep 30, 2021 | 2,960.01 |
| Dec 31, 2020 | 108.46 Mn |